about
How can mathematical models advance tuberculosis control in high HIV prevalence settings?Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.Methodological Issues to Consider When Collecting Data to Estimate Poverty Impact in Economic Evaluations in Low-income and Middle-income CountriesCost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India.Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.The Costs of Delivering Integrated HIV and Sexual Reproductive Health Services in Limited Resource Settings.Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.Does integration of HIV and SRH services achieve economies of scale and scope in practice? A cost function analysis of the Integra InitiativeOptimising the cost and delivery of HIV counselling and testing services in Kenya and Swaziland.Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income CountriesForeword: Health Economic Evaluations in Low- and Middle-income Countries: Methodological Issues and Challenges for Priority Setting.Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at ScaleCosts and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience.Financing the HIV response in sub-Saharan Africa from domestic sources: Moving beyond a normative approach.Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.The economic burden of TB diagnosis and treatment in South Africa.Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.A cluster randomised trial to evaluate the effect of optimising TB/HIV integration on patient level outcomes: the "merge" trial protocol.Estimating unbiased economies of scale of HIV prevention projects: a case study of Avahan.Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa.Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa.Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India.Patient costs of accessing collaborative tuberculosis and human immunodeficiency virus interventions in Ethiopia.Reforming tuberculosis control in Ukraine: results of pilot projects and implications for the national scale-up of DOTS.Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens.Health care seeking behaviour for tuberculosis symptoms in Kiev City, Ukraine.Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study.Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modellingThe growing burden of non-communicable disease among persons living with HIV in Zimbabwe.Impact of integration of sexual and reproductive health services on consultation duration times: results from the Integra Initiative.Evidence-informed policy making at country level: lessons learned from the South African Tuberculosis Think Tank.Measuring income for catastrophic cost estimates: Limitations and policy implications of current approachesCost of point-of-care lateral flow urine lipoarabinomannan antigen testing in HIV-positive adults in South AfricaAn intervention to optimise the delivery of integrated tuberculosis and HIV services at primary care clinics: results of the MERGE cluster randomised trialVariation in the quality and out-of-pocket cost of treatment for childhood malaria, diarrhoea, and pneumonia: Community and facility based care in rural Uganda
P50
Q26824057-9D7E11CE-1255-45E2-9CDB-261AF14DDAA1Q30830344-B3287F73-3289-46C6-B1EB-078D97BBCC53Q31037190-EF8C6742-0B23-462D-A38D-FD96F3824DEAQ33800939-3DD110FE-6AEF-4B12-BB8D-E8C96A8EA4BFQ34278022-35E883BB-1061-49A3-9EC9-6A1D8EFB8139Q34395434-FC97E4D6-E3CE-49A7-BF23-0CC04F5F241BQ35561173-D7723FC1-E7E5-4040-ADA5-6EC8880E51CEQ35662072-EDADE29D-08BA-457E-864B-0DA2889B0997Q35881727-38000480-F022-4413-9675-920126084903Q36024119-C3165D3D-7977-43C4-9FB6-6B32AF8892F0Q36665407-5F863363-968F-429B-A93A-A50EB42ED516Q36678386-99B561D6-A17C-4965-904E-7EFE47212991Q37295972-BC883590-C771-4809-A816-D503091C4530Q37343851-D4572D60-DA6D-418E-9C19-CB534CC421B9Q37343926-99604C94-2D1E-40DC-9C20-DB3A01FCA0F4Q37967142-6706B866-F96B-4119-BA3E-428A5AD33910Q38807911-C51B9AAA-228D-4922-B58A-AC48008F1AD3Q38853460-D8276BF9-A5D4-410A-92F1-B5B5974A90B2Q39009157-76ED3F78-2A94-4BA3-BD50-6A18CD1B0F02Q39079068-1963BC26-A6F7-414C-B9EA-C56810CDCC74Q39150195-01B6A398-722E-4C06-BEE0-9BFD210059C3Q39196549-94D09EED-BDE8-4572-A025-E2D4EC8CF511Q39245552-86E2DF78-C74D-4255-AD2D-852FD6519314Q39278224-53BCEE90-C776-4509-B201-1DA597501405Q39381653-83682B7B-3701-41DB-87D9-F5C0D4A601B0Q39414270-AD4F93D9-B59C-4589-AFEA-99AF7121878EQ39555096-45C49597-DD24-4D7E-9536-F4CA2FC83D73Q39555104-A810141D-AE11-4815-A24A-CC0118558647Q39555115-5D3233F0-2923-47E8-A554-93D54388A852Q39634714-8CB37B08-E988-49AA-960D-2555A5F7148BQ39751116-8330880D-104F-40C1-9250-93274458821AQ42377337-40A25E1F-FE03-4FD5-84E8-52C669C337A1Q42546968-944CB762-8092-4835-9AD2-5681D3A75567Q47646683-3902B6E4-5140-4C3F-BB7F-C002ACC8A882Q50193754-CF47905F-5533-4277-92B1-6E1BA1CA7DE2Q54940389-7BFA9E6C-2906-405E-9438-E5C94D40D930Q57921926-F7B40066-4D8D-4EAE-8EF8-5CFFEDA60BA9Q58778152-B229CE8C-C198-4EF4-8B43-7866B5055A6BQ59181253-8BAC8F05-2382-4DF4-A9CE-A3ACFF14721EQ59811450-A77178EB-3873-4F9D-923C-7848539577A4
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
Anna Vassall
@en
Vassall A
@nl
type
label
Anna Vassall
@en
Vassall A
@nl
altLabel
Vassall A
@en
prefLabel
Anna Vassall
@en
Vassall A
@nl
P106
P31
P496
0000-0002-2911-1375